Agilum Releases Additional RWD Survival Rate Analytics for HCQ or CQ and Acetazolamide

Updated daily at 8:30 AM ET

By: William D. Kirsh, DO, MPH, CMIO, Agilum Healthcare Intelligence, Inc. and
Travis J. Leonardi, RPh, C.P., CEO of Agilum Healthcare Intelligence, Inc.


Through its Comparative Rapid Cycle Analytics™ (CRCA™) solution, Agilum Healthcare Intelligence seeks to leverage its comprehensive, longitudinal patient database to deliver updates on current and new treatment regimens – providing greater transparency into the resulting outcomes for various cohorts of COVID-19 patients. This data supports more detailed observations into the survival rate by drug treatment regimens for COVID-19 patients with and without comorbid conditions (determined by a pulmonary and/or cardiac diagnosis within the past 12 calendar months). Specifically, this information is grouped into a known COVID-19 regimen: hydroxychloroquine or chloroquine and acetazolamide (“HCQ or CQ and Acetazolamide”). Observations are based on:

  • Real-world data (RWD) from inpatient care including drug dispensation data
  • A representative sampling of patients in hospitals across the United States
  • Dynamic, real-time, continuously updated information

With the rapidly evolving incidence of COVID-19, this report will be refreshed regularly to show near real-time trends of patient outcomes based on specific drug treatment regimens.

COVID-19 Nationwide Real-World Data (RWD) Inpatient Drug Regimen Analysis:
Drug Protocols of Hydroxychloroquine or Chloroquine and Acetazolamide


Clinicians have observed and reported that chest x-ray and CT scan lung imaging of COVID-19 patients shows patterns consistent with High Altitude Pulmonary Edema (HAPE). Acetazolamide is a common treatment for this condition, and as such, we have witnessed a measurable increase in the use of this medication in combination with hydroxychloroquine or chloroquine in the treatment of COVID-19 patients.

In the continued interest of producing information to support and advance the care of these patients, we seek to provide an individualized look at the real-world data (RWD) surrounding this drug regimen.


By leveraging Agilum’s Comparative Rapid Cycle Analytics™ (CRCA™) platform, Agilum has written protocols to analyze real-world data (RWD) from the inpatient care setting taking place in hospitals nationwide treating patients with COVID-19. The data tables contained herein were constructed using RWD to create an analytical approach, as opposed to a clinical study such as a randomized control trial. In doing so, we seek to advance the rapidly evolving body of knowledge pertaining to the care and treatment of patients with COVID-19 using near real-time longitudinal patient data. The data will be updated and republished continuously as available.


  • Examined inpatient dispensations of select drugs from March 1, 2020 through yesterday from hospitals nationwide. Leveraged a current, near-real-time data stream to ensure timeliness and accuracy.
  • Grouped drugs into a specific known COVID-19 regimen: hydroxychloroquine or chloroquine and acetazolamide (“HCQ or CQ and Acetazolamide”).
  • Analyzed patients by age and gender on each regimen for outcomes associated with survival rates.
  • Analysis factors comorbid conditions related to cardiac and pulmonary diseases, using ICD-10 CM diagnosis codes corresponding to the respective clinical classes as defined by the Agency for Healthcare Research and Quality (AHRQ).
  • All patients in this analysis were hospitalized and treated with the drug regimens listed herein. The analysis does not contain patients who were treated outside of these drug regimens.




  • Based on observation of real-world data analytics, not a clinical study or trial.
  • This information is for observational purposes only and is not a recommendation, endorsement or advice as to any medical or therapeutic treatment option. We advise readers to consult with medical professionals and public health authorities regarding treatment of any COVID-19 infection.
  • The information is subject to change without notice. The information is solely based on data received.
  • All product names and trademarks are the property of their respective owners.

To download a recent PDF of this analysis or request a PDF reflecting the real-time data published above, simply fill out the form below. For more information about this analysis or Agilum Healthcare Intelligence solutions, please call 877.AGLMHCI (245.6424).